Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.
Milind Desai, MD, MBA, and Michelle M. Kittleson, MD, PhD, review the clinical trial data of mavacamten, the first FDA-approved cardiac myosin inhibitor for the treatment of oHCM.